Safety and pharmacokinetics of oral and longacting injectable cabotergravir or longacting rilpivirine in virologically supressed adolescents with HIV IMPAACT 2017MOCHAaa phase 12 multicentre openlebel noncomparative dosefinding study

Simple item page
dc.article.end-page221en
dc.article.start-page211en
dc.citation.doi10.1016/S2352-3018(23)00300-4en
dc.contributor.authorAditya Guaren
dc.contributor.authorE Capparellien
dc.contributor.authork calabreseen
dc.contributor.authork baltrusaitisen
dc.contributor.authorFaeezah Patelen
dc.date.accessioned2025-01-21T13:34:48Z
dc.date.available2025-01-21T13:34:48Z
dc.departmentWITS REPRODUCTIVE HEALTH AND HIV INSTITUTEen
dc.facultyFACULTY OF HEALTH SCIENCESen
dc.identifier.citationWOSen
dc.identifier.issn2352-3018en
dc.identifier.urihttps://hdl.handle.net/10539/43571
dc.journal.titleSafety and pharmacokinetics of oral and longacting injectable cabotergravir or longacting rilpivirine in virologically supressed adolescents with HIV IMPAACT 2017MOCHAaa phase 12 multicentre openlebel noncomparative dosefinding studyen
dc.journal.volume11en
dc.titleSafety and pharmacokinetics of oral and longacting injectable cabotergravir or longacting rilpivirine in virologically supressed adolescents with HIV IMPAACT 2017MOCHAaa phase 12 multicentre openlebel noncomparative dosefinding studyen
dc.typeJournal Articleen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Journal Article.pdf
Size:
794.25 KB
Format:
Adobe Portable Document Format
Description:
Bitstream uploaded by REST Client
Download

Collections

Academic Wits Research Outputs (All submissions)